[go: up one dir, main page]

MA27136A1 - Association nouvelle. - Google Patents

Association nouvelle.

Info

Publication number
MA27136A1
MA27136A1 MA27581A MA27581A MA27136A1 MA 27136 A1 MA27136 A1 MA 27136A1 MA 27581 A MA27581 A MA 27581A MA 27581 A MA27581 A MA 27581A MA 27136 A1 MA27136 A1 MA 27136A1
Authority
MA
Morocco
Prior art keywords
new association
pde3
pde4
depositor
priorities
Prior art date
Application number
MA27581A
Other languages
English (en)
Inventor
Rolf Beume
Christian Weimar
Daniela Bundschuh
Stefan-Lutz Wollin
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27136A1 publication Critical patent/MA27136A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

DEPOSANT société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES EP 19 Septembre 2001 01000474.5 Voir en annexe le titre de l'invention et le texte de l'abrégé Association nouvelle La présente invention concerne l'administration en association d'inhibiteurs de PDE4 ou PDE3/4 et d'antagonistes des récepteurs de leucotriènes pour le traitement de troubles du tractus respiratoire.
MA27581A 2001-09-19 2004-03-18 Association nouvelle. MA27136A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01000474 2001-09-19

Publications (1)

Publication Number Publication Date
MA27136A1 true MA27136A1 (fr) 2005-01-03

Family

ID=8176066

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27581A MA27136A1 (fr) 2001-09-19 2004-03-18 Association nouvelle.

Country Status (25)

Country Link
US (1) US20050014762A1 (fr)
EP (1) EP1429843B1 (fr)
JP (1) JP2005505570A (fr)
KR (1) KR20040044946A (fr)
CN (1) CN100346831C (fr)
AT (1) ATE349243T1 (fr)
BR (1) BR0212582A (fr)
CA (1) CA2460442A1 (fr)
CO (1) CO5560584A2 (fr)
CY (1) CY1106365T1 (fr)
DE (1) DE60217139T2 (fr)
DK (1) DK1429843T3 (fr)
EA (1) EA007736B1 (fr)
ES (1) ES2279004T3 (fr)
HU (1) HUP0500078A3 (fr)
IL (2) IL160272A0 (fr)
MA (1) MA27136A1 (fr)
MX (1) MXPA04002560A (fr)
NO (1) NO331885B1 (fr)
NZ (1) NZ532279A (fr)
PL (1) PL205927B1 (fr)
PT (1) PT1429843E (fr)
SI (1) SI1429843T1 (fr)
WO (1) WO2003024488A2 (fr)
ZA (1) ZA200402653B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
US20100210611A1 (en) * 2007-10-25 2010-08-19 Roch Thibert Combination therapy
WO2012168907A1 (fr) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant du révamilast et du montélukast ou du zafirlukast
WO2014012954A1 (fr) 2012-07-18 2014-01-23 Takeda Gmbh Traitement de l'asthme sévère partiellement régulé ou non régulé
SG11201505878UA (en) 2013-02-19 2015-09-29 Pfizer Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
WO2015063669A1 (fr) 2013-10-30 2015-05-07 Wockhardt Limited Compositions pharmaceutiques comprenant une combinaison de roflumilast et d'acébrophylline ou de leurs sels pharmaceutiquement acceptables
CA2936332A1 (fr) 2014-01-22 2015-07-30 Takeda Gmbh Traitement de l'asthme grave partiellement controle ou non controle avec un inhibiteur de pde4 (et en combinaison avec un modificateur des leucotrienes)
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
ES2733502T3 (es) 2014-08-06 2019-11-29 Pfizer Compuestos de imidazopiridazina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028986A1 (es) * 1999-02-23 2003-06-04 Smithkline Beecham Corp USO DE UN INHIBIDOR DE PDE4 EN LA FABRICACIoN DE UNA PREPARACIoN DE LIBERACIoN CONTROLADA; FORMULACION DE LIBERACION CONTROLADA PARA EL TRATAMIENTO DE COPD, UN PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIoN FARMACÉUTICA
AU777012B2 (en) * 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
MY134008A (en) * 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
TR200201880T2 (tr) * 2000-01-31 2002-11-21 Pfizer Products Inc. PDE4 izozimerlerinin seçici önleyicileri olarak faydalı nikotinamit benzobağlı-heterosiklil türevleri
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
WO2001090076A1 (fr) * 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Inhibiteur de pde4 n-oxyde dichloropyridinyl benzamide a substitution fluoroalcoxy

Also Published As

Publication number Publication date
ZA200402653B (en) 2005-02-14
EP1429843B1 (fr) 2006-12-27
IL160272A (en) 2008-03-20
ES2279004T3 (es) 2007-08-16
CY1106365T1 (el) 2011-10-12
BR0212582A (pt) 2004-10-13
CA2460442A1 (fr) 2003-03-27
NZ532279A (en) 2006-02-24
SI1429843T1 (sl) 2007-06-30
KR20040044946A (ko) 2004-05-31
NO331885B1 (no) 2012-04-30
CN1655846A (zh) 2005-08-17
IL160272A0 (en) 2004-07-25
HK1066752A1 (en) 2005-04-01
DK1429843T3 (da) 2007-04-30
ATE349243T1 (de) 2007-01-15
US20050014762A1 (en) 2005-01-20
WO2003024488A3 (fr) 2003-09-04
PL205927B1 (pl) 2010-06-30
EA200400416A1 (ru) 2004-12-30
PT1429843E (pt) 2007-03-30
CN100346831C (zh) 2007-11-07
DE60217139T2 (de) 2007-10-04
HUP0500078A3 (en) 2010-07-28
CO5560584A2 (es) 2005-09-30
WO2003024488A2 (fr) 2003-03-27
EP1429843A2 (fr) 2004-06-23
HUP0500078A2 (hu) 2005-04-28
PL367414A1 (en) 2005-02-21
MXPA04002560A (es) 2004-05-31
JP2005505570A (ja) 2005-02-24
EA007736B1 (ru) 2006-12-29
DE60217139D1 (de) 2007-02-08
NO20041595L (no) 2004-06-16

Similar Documents

Publication Publication Date Title
EP1370211A4 (fr) Co-administration de l'agoniste du recepteur de la melanocortine et inhibiteur de phosphodiesterase pour le traitement de troubles associes a l'amp cyclique
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
TNSN07063A1 (fr) Utilisations therapeutiques d'inhibiteurs de rtp801
EP1357908A4 (fr) Acyl-sulfamides pour le traitement de l'obesite, du diabete et des troubles lipidiques
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
MA27311A1 (fr) Utilisation d'inhibiteurs de cetp et facultativement d'inhibiteurs de hmg-coa-reductase et/ou d'agents antihypertensifs
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
EP1604664A4 (fr) Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
TNSN01053A1 (fr) Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
FR2867778B1 (fr) Utilisation de derives d'indazolecarboxamides pour la preparation d'un medicament destine au traitement et a la prevention du paludisme
MA27136A1 (fr) Association nouvelle.
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
EP1418876A4 (fr) Administration de metabolites de l'oestradiol pour le traitement ou la prevention de l'obesite, du syndrome metabolique, du diabete et de troubles vasculaires et renaux
MA26779A1 (fr) Derives de 1-arenesulfonyl-2-aryl-pyrrolidine et de piperidine pour le traitement de troubles du systeme nerveux central.
MA27682A1 (fr) Compositions de valdecoxib a delitement intra-oral
BG105302A (en) Means for improving cognition
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
DZ3027A1 (fr) Composés et procédés pour le traitement de l'asthme, de l'allergie et des troubles inflammatoires.
PT946157E (pt) Utilizacao topica de agonistas kapa-opioides para o tratamento da dor ocular
SE9903995D0 (sv) New combination
MA27539A1 (fr) Nouvelle combinaison synergique contenant du roflumilast et du formoterol
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon